Welcome to our dedicated page for Scorpius Holdings news (Ticker: SCPX), a resource for investors and traders seeking the latest updates and insights on Scorpius Holdings stock.
Scorpius Holdings Inc (SCPX) is a leading contract development and manufacturing organization (CDMO) accelerating biologic and cell therapy programs through integrated analytical testing, process development, and advanced manufacturing services. This news hub provides investors and industry professionals with essential updates on the company's operational milestones, regulatory developments, and strategic partnerships.
Access real-time updates on Scorpius Holdings' progress in biomanufacturing innovation, including earnings announcements, facility expansions, and collaborations supporting pandemic preparedness initiatives. Our curated news collection enables efficient tracking of critical developments impacting the company's position in the biologics CDMO sector.
Key content categories include clinical manufacturing achievements, quality system enhancements, analytical method validations, and strategic alliances with biotech innovators. All updates are sourced directly from official company communications and verified industry reports.
Bookmark this page for streamlined access to Scorpius Holdings' latest advancements in cell therapy manufacturing and bioprocess optimization. Check regularly for updates on technology platform deployments and regulatory submissions that demonstrate the company's growing capabilities in complex therapeutic development.
Scorpius Holdings, an integrated CDMO, has announced the pricing of its public offering of 60,000,000 common units or pre-funded units at $0.10 per unit. Each unit includes one share of common stock (or a pre-funded warrant) and a common warrant to purchase one share at $0.12. Gross proceeds are expected to be $6,000,000 before expenses, with an option for underwriters to purchase up to an additional 9,000,000 units to cover over-allotments. The offering is set to close on May 16, 2024. Proceeds will fund working capital, general purposes, and repay a $750,000 note. ThinkEquity is the sole manager for this offering.
Scorpius Holdings, Inc. announced the appointment of Shari Udoff-McDonald as VP of Business Development. With over 25 years of experience in biopharma business development, she will lead the business development, marketing, and proposals teams to address the strong demand for flexible mammalian and microbial biomanufacturing services. Scorpius is poised for growth with its commitment to transparency and flexibility in CDMO partnerships.
Scorpius Holdings, Inc provided a 2023 year-end business update highlighting a 570% sequential revenue increase in the fourth quarter of 2023. The company reported $4.8 million in revenue from continuing operations, leading to a positive outlook for significant growth in 2024 and beyond. Scorpius aims to capitalize on the growing large molecule drug substance CDMO market, anticipating becoming cash flow positive by early 2025. The company's financial results showed $6.6 million in contract revenue for 2023, along with increased costs and expenses compared to the previous year.
